autophagy related 5Genealiases: APG5 · APG5-LIKE · APG5L · ASP · SCAR25 · hAPG5
Q-omics provides the consensus-scored ATG5 profile across patient tissues and cancer cell-line models. ATG5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ATG5 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ATG5 protein abundance shows 24,020 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, HNSC, and LSCC as cancer lineages where ATG5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATG5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATG5 survival associations across molecular data types. ATG5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATG5 RNA expression–survival associations across cancer types. High ATG5 expression shows unfavorable associations in CESC, HNSC, LIHC, KIRP and BRCA, but favorable associations in SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify CESC as the clearest survival context for ATG5 RNA expression.
This table summarizes ATG5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATG5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATG5 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, BLCA and STAD. The HNSC box plot shows higher ATG5 RNA expression in tumor versus normal tissue (log2 FC = +0.993, t-test p < 0.001).
This table shows molecular features associated with ATG5 in patient tissues and cancer cell lines. In patient samples, ATG5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATG5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
